AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21842019 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush age at 12 weeks
Number of subjects: 110
Study 21842019 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush age at 16 weeks
Number of subjects: 110
Study 21842019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual/palatal surfaces
Number of subjects: 110
Study 21842019 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush wear index
Number of subjects: 110
Study 21842019 — intervention group
Group type: COMPARATOR
Intervention: Lowest wear, moderate wear, highest wear toothbrushes
Number of subjects: 110
Study 19606086 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS applied to the DLPFC
Number of subjects: 0
Study 19606086 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15956071 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-gluconate 62.5 mg
Number of subjects: 14
Study 15956071 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-gluconate 125 mg
Number of subjects: 14
Study 15956071 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg iron-gluconate)
Number of subjects: 14
Study 15956071 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-gluconate (both doses)
Number of subjects: 14
Study 11756982 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus IL-2
Number of subjects: 9
Study 11756982 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 9
Study 10417454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-bupivacaine 0.1% mixture
Number of subjects: 106
Study 10417454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-bupivacaine 0.2% mixture
Number of subjects: 106
Study 10417454 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl alone
Number of subjects: 106
Study 7576328 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved STD treatment services
Number of subjects: 12000
Study 7576328 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard STD treatment)
Number of subjects: 12000
Study 2206015 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 treatment
Number of subjects: 0
Study 6989464 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy with platelet antiaggregants
Number of subjects: 0
Study 6989464 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31431370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia (HT) combined with radiation treatment (RT)
Number of subjects: 0
Study 31431370 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging-guided focused ultrasound (MRgFUS)
Number of subjects: 0
Study 30570289 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined contact
Number of subjects: 339
Study 28566392 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta ceramic total hip arthroplasty (THA)
Number of subjects: 252
Study 26442158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 70
Study 23337364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling (EC)
Number of subjects: 204
Study 23337364 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy (mDOT)
Number of subjects: 204
Study 23337364 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 204
Study 21324181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential behaviour tailoring condition
Number of subjects: 0
Study 21324181 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous behaviour tailoring condition
Number of subjects: 0
Study 21324181 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18993042 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (IV NAC 150mg/kg on the first day followed by 50mg/kg/day for three days)
Number of subjects: 27
Study 18993042 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 17535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 0
Study 17535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 17535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 0
Study 17535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 15581383 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg ODT
Number of subjects: 670
Study 15581383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study 11307043 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg L‐Dopa
Number of subjects: 16
Study 11307043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9484419 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton spectroscopy in subjects with idiopathic narcolepsy
Number of subjects: 24
Study 9484419 — intervention group
Group type: COMPARATOR
Intervention: Proton spectroscopy in normal subjects
Number of subjects: 24
Study 9484419 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton spectroscopy in subjects who slept during the scan
Number of subjects: 24
Study 7699215 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVPI)
Number of subjects: 30
Study 7699215 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine hydrochloride (Control)
Number of subjects: 30
Study 2728828 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg buprenorphine
Number of subjects: 45
Study 2728828 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.045 mg buprenorphine
Number of subjects: 45
Study 2728828 — intervention group
Group type: COMPARATOR
Intervention: hyperbaric bupivacaine
Number of subjects: 45
Study 5809554 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose diet
Number of subjects: 19
Study 5809554 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet after 14 days of high sucrose diet
Number of subjects: 19
Study 30312895 — intervention group
Group type: EXPERIMENTAL
Intervention: Low home practice condition
Number of subjects: 84
Study 30312895 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium home practice condition
Number of subjects: 84
Study 30312895 — intervention group
Group type: EXPERIMENTAL
Intervention: High home practice condition
Number of subjects: 84
Study 30312895 — intervention group
Group type: COMPARATOR
Intervention: Flexible home practice schedule
Number of subjects: 84
Study 27313171 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTRC Shoulder Injury Prevention Programme (exercise programme delivered 3 times per week for 7 months)
Number of subjects: 660
Study 27313171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 660
Study 27313171 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTRC Shoulder Injury Prevention Programme
Number of subjects: 660
Study 25542155 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC priority driven approach to pelvic trauma management
Number of subjects: 20
Study 25542155 — intervention group
Group type: COMPARATOR
Intervention: Standard pelvic trauma teaching without ABC concept
Number of subjects: 20
Study 22952194 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape consumption
Number of subjects: 40
Study 22952194 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 40
Study 20453069 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors at admission for bleeding
Number of subjects: 15156
Study 20453069 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gastroduodenal ulcer
Number of subjects: 15156
Study 20453069 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior bleeding
Number of subjects: 15156
Study 20453069 — intervention group
Group type: EXPERIMENTAL
Intervention: Low platelet count
Number of subjects: 15156
Study 20453069 — intervention group
Group type: EXPERIMENTAL
Intervention: Other bleeding risk factors
Number of subjects: 15156
Study 18505951 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular catheterization
Number of subjects: 750
Study 18505951 — intervention group
Group type: COMPARATOR
Intervention: Femoral catheterization
Number of subjects: 750
Study 16603855 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% PRO 2000 gel
Number of subjects: 36
Study 16603855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000 gel
Number of subjects: 36
Study 16603855 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study 12614254 — intervention group
Group type: EXPERIMENTAL
Intervention: Testim 100 mg/day
Number of subjects: 208
Study 12614254 — intervention group
Group type: EXPERIMENTAL
Intervention: Testim 50 mg/day
Number of subjects: 208
Study 12614254 — intervention group
Group type: COMPARATOR
Intervention: Andropatch
Number of subjects: 208
Study 10568572 — intervention group
Group type: EXPERIMENTAL
Intervention: Campath‐1H monoclonal antibody treatment (5-day pulse)
Number of subjects: 27
Study 9005794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg intravenously twice a day for 4 to 6 days, then orally for 4 to 6 days)
Number of subjects: 35
Study 9005794 — intervention group
Group type: COMPARATOR
Intervention: Control group (broad spectrum antibiotics such as amplox, gentamicin, and 3rd generation cephalosporins)
Number of subjects: 35
Study 1834115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracosactrin
Number of subjects: 97
Study 1834115 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 97
Study 6751888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 24
Study 6751888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31473982 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered empowerment program
Number of subjects: 90
Study 31473982 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 30745118 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with long-term androgen deprivation therapy
Number of subjects: 0
Study 30745118 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy or next-generation hormone therapies
Number of subjects: 0
Study 28757109 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily
Number of subjects: 22
Study 25901540 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 40
Study 25901540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23392919 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDEO group watched video clips showing repetitive finger movements paced at 3 Hz
Number of subjects: 20
Study 23392919 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOUSTIC group listened to an acoustic cue paced at 3 Hz
Number of subjects: 20
Study 23392919 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (static hand video)
Number of subjects: 20
Study 23392919 — intervention group
Group type: EXPERIMENTAL
Intervention: On and off medication states (for VIDEO group)
Number of subjects: 20
Study 22134562 — intervention group
Group type: EXPERIMENTAL
Intervention: CLNP 1.2%-BPO 3% gel
Number of subjects: 1319
Study 22134562 — intervention group
Group type: COMPARATOR
Intervention: CLNP 1.2% gel
Number of subjects: 1319
Study 22134562 — intervention group
Group type: COMPARATOR
Intervention: BPO 3% gel
Number of subjects: 1319
Study 22134562 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 1319
Study 22134562 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1319
Study 19549737 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl supplementation (100 mmol/day) during telmisartan treatment with or without HCT
Number of subjects: 32
Study 19549737 — intervention group
Group type: COMPARATOR
Intervention: Placebo during telmisartan treatment with or without HCT
Number of subjects: 32
Study 17539709 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + ABBM + GTR
Number of subjects: 24
Study 17539709 — intervention group
Group type: COMPARATOR
Intervention: ABBM + GTR
Number of subjects: 24
Study 15085888 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of docosahexaenoic acid (DHA) supplementation
Number of subjects: 20
Study 15085888 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-supplemented)
Number of subjects: 20
Study 15887725 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical itraconazole (1%)
Number of subjects: 54
Study 15887725 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and systemic itraconazole
Number of subjects: 54
Study 15887725 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 10767783 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and genetic testing for BRCA1 and BRCA2 mutations
Number of subjects: 213
Study 10767783 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and genetic testing
Number of subjects: 213
Study 9088580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking, 16 cigarettes/day
Number of subjects: 12
Study 9088580 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine, 15 mg/day
Number of subjects: 12
Study 9088580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray, 24-1 mg doses/day
Number of subjects: 12
Study 9088580 — intervention group
Group type: COMPARATOR
Intervention: Placebo nicotine nasal spray, 24 doses/day
Number of subjects: 12
Study 7680306 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (COPP/ABVD scheme, with or without mediastinal irradiation)
Number of subjects: 49
Study 7680306 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 patients with normal hearts)
Number of subjects: 49
Study 3749604 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceglutamide aluminum (N‐acetyl‐L‐glutamine aluminum complex) administered in multiple daily doses (total of 3290 mg over 14 days)
Number of subjects: 12
Study 3749604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3749604 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceglutamide aluminum
Number of subjects: 12
Study 29750760 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine transversus abdominis plane block
Number of subjects: 21
Study 29750760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine pain pump
Number of subjects: 21
Study 29750760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 26862079 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol assessment
Number of subjects: 17266
Study 26862079 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to cut back on drinking
Number of subjects: 17266
Study 26862079 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about treatment for alcohol abuse
Number of subjects: 17266
Study 26862079 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about treatment for alcohol dependence
Number of subjects: 17266
Study 25413081 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione and testosterone levels in acne cases
Number of subjects: 430
Study 25413081 — intervention group
Group type: EXPERIMENTAL
Intervention: 17α-hydroxyprogesterone (17-OHP) levels in male acne cases
Number of subjects: 430
Study 25413081 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol levels in female acne cases
Number of subjects: 430
Study 25413081 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of androstenedione and testosterone
Number of subjects: 430
Study 25413081 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of 17-OHP
Number of subjects: 430
Study 25413081 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of estradiol
Number of subjects: 430
Study 23534177 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction techniques (toy)
Number of subjects: 0
Study 23534177 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction techniques (music)
Number of subjects: 0
Study 23534177 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20356492 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue-type plasminogen activator (rt-PA) 50 mg
Number of subjects: 118
Study 20356492 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human tissue-type plasminogen activator (rt-PA) 100 mg
Number of subjects: 118
Study 20356492 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 118
Study 18397843 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical trials (n = 18)
Number of subjects: 114
Study 18397843 — intervention group
Group type: COMPARATOR
Intervention: Medical trials (n = 81)
Number of subjects: 114
Study 18397843 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical trials (n = 6)
Number of subjects: 114
Study 18397843 — intervention group
Group type: COMPARATOR
Intervention: Medical trials (n = 93)
Number of subjects: 114
Study 15997603 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT) and attention‐shaping sequence
Number of subjects: 31
Study 15997603 — intervention group
Group type: COMPARATOR
Intervention: Equivalent hours of treatment in the same intensive behavioral rehabilitation program
Number of subjects: 31
Study 12764404 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (group DT; 100 patients)
Number of subjects: 171
Study 12764404 — intervention group
Group type: COMPARATOR
Intervention: Untreated (group DU; 71 patients)
Number of subjects: 171
Study 12764404 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I/ARB treatment in DT group
Number of subjects: 171
Study 12764404 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for microalbuminuria
Number of subjects: 171
Study 10334417 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vectorcardiography ST segment monitoring (cVST) for 24 hours combined with cardiac troponin T (cTnT) determination.
Number of subjects: 232
Study 10334417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin T (cTnT) determination at admission.
Number of subjects: 232
Study 10334417 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestudy medication with calcium antagonists.
Number of subjects: 232
Study 10334417 — intervention group
Group type: EXPERIMENTAL
Intervention: One ST segment episode or more during monitoring.
Number of subjects: 232
Study 1758253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 26
Study 1758253 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) analgesia
Number of subjects: 26
Study 30044247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg/day
Number of subjects: 564
Study 30044247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 564
Study 30044247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 30044247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone (combined 20 and 40 mg/day)
Number of subjects: 564
Study 26531062 — intervention group
Group type: EXPERIMENTAL
Intervention: mTPE (Octonova with Plasmaflo filter)
Number of subjects: 21
Study 26531062 — intervention group
Group type: COMPARATOR
Intervention: cTPE (Spectra Optia apheresis system)
Number of subjects: 21
Study 26531062 — intervention group
Group type: EXPERIMENTAL
Intervention: mTPE
Number of subjects: 21
Study 26531062 — intervention group
Group type: COMPARATOR
Intervention: cTPE
Number of subjects: 21
Study 25434609 — intervention group
Group type: EXPERIMENTAL
Intervention: Smith Machine squat (SM)
Number of subjects: 14
Study 25434609 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbell back squat (BB)
Number of subjects: 14
Study 25434609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendo-destabilizing bar squat (TBB)
Number of subjects: 14
Study 22608316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotop vitrification of half of mature oocytes
Number of subjects: 44
Study 22608316 — intervention group
Group type: COMPARATOR
Intervention: Control oocytes
Number of subjects: 44
Study 19694628 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine-quetiapine (375 mg/day, 600 mg/day)
Number of subjects: 122
Study 19694628 — intervention group
Group type: COMPARATOR
Intervention: venlafaxine
Number of subjects: 122
Study 19694628 — intervention group
Group type: COMPARATOR
Intervention: imipramine (plasma-levels 200-300 microg/l)
Number of subjects: 122
Study 17907276 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidementia drug treatment
Number of subjects: 122
Study 17907276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia of the Alzheimer type (DAT)
Number of subjects: 122
Study 17907276 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 122
Study 17907276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEIs)
Number of subjects: 122
Study 17907276 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations of therapeutic impact
Number of subjects: 122
Study 16902901 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient pulmonary rehabilitation (AHB)
Number of subjects: 207
Study 14659514 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 71
Study 14659514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 10971304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (PSE) 180 mg
Number of subjects: 22
Study 10971304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8638865 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 13
Study 8638865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8638865 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 13
Study 1569238 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 5 mg once daily
Number of subjects: 317
Study 1569238 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg once daily
Number of subjects: 317
Study 1569238 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg once daily
Number of subjects: 317